accountBill Berkrot NEW YORK, May 18 (Reuters) - More than 60 percent of lung cancer patients who received Pfizer (PFE.N While the drug was not compared to other medicines or placebo -- a higher standard of clinical trial -- the results marked the first overall...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer lung cancer drug shows survival benefit
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account